| INTRODUCTION
The implantable cardioverter-defibrillator (ICD) is an important tool in the prevention of sudden cardiac death due to arrhythmias in patients with heart failure (HF) with heart failure with reduced ejection fraction (HFrEF). However, appropriate and inappropriate ICD therapies result in pain and subsequent psychological apprehension, anxiety, Abbreviations: ATP, anti-tachycardia pacing; CM, cardiomyopathy; CRT, cardiac resynchronization therapy; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; HR, hazard ratio; ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; VT, ventricular tachycardia. and impaired quality of life. [1] [2] [3] Furthermore recurrent inappropriate shocks may lead to worsening HF. 4, 5 Medical therapy for HFrEF includes beta adrenergic blockers of which three (carvedilol, metoprolol succinate, and bisoprolol) have been shown to improve mortality. [6] [7] [8] There have been no direct comparative trials to support the use of one beta-blocker over the other in HFrEF, specifically in reducing cardiac arrhythmias and thus preventing ICD therapies. The aim of the current study was to compare the antiarrhythmic efficacy of carvedilol and metoprolol succinate in the treatment in HFrEF in patients with an ICD.
2 | METHODS
| Study design
All patients with an ICD (including cardiac resynchronization therapy
[CRT]) who were followed at the device clinic at University of Arkansas between January 2012 and June 2017 were screened in this retrospective study (n = 569). Exclusion criteria included (a) patients who had less than two follow-up visits were excluded (n = 279), Statistical analysis was performed using MedCalc (version 18, Ostend, Belgium). Categorical variables were depicted using percentages and compared using χ 2 test for while continuous variables were described by mean +/− SD and compared using t tests. Kaplan-Meier analysis was performed to compare survival free of primary and secondary endpoints, and the survival curves were compared using log rank test. To control for other risk factors for arrhythmias in this population (chosen based on widely accepted risk and significance on univariate analysis P < 0.1), Cox regression analysis was performed.
A P-value <0.05 was considered statistically significant.
| RESULTS
A total of 225 patients were included in the analysis ( Figure 1 ). Table 1 
| DISCUSSION
The major finding of this study was that carvedilol was superior in pre- Resynchronization Therapy. 15 In this post hoc analysis, carvedilol was associated with a reduction in incidence of ventricular arrhythmias which barely reached statistical significance (0.80 [95% CI: 0.63 to 1.00], P = 0.05) compared with metoprolol. However, 12% in the metoprolol arm used the tartrate preparation which is known to be inferior to carvedilol. 16 In addition, there were significant baseline differences (lesser number of ischemic CM in carvedilol group) which may have affected the outcome. In the current study, there was no significant difference in baseline parameters between carvedilol and metoprolol succinate and patients on metoprolol tartrate were excluded.
In the present study, carvedilol was not associated with a reduction in inappropriate ICD therapy for supraventricular tachyarrhythmias compared to metoprolol succinate. This can be explained by the fact that in clinically used doses, the effects of carvedilol and metoprolol on the atrioventricular node are similar which may result in reduced ventricular rate response in patients with supraventricular arrhythmias. [17] [18] [19] The results of this study differ from a prior post hoc analysis of the MADIT CRT study which showed that carvedilol was superior to metoprolol in reducing inappropriate ICD therapies. 20 The present study included patients with both CRT and non-CRT devices and may have been underpowered to detect a significant difference.
| STUDY LIMITATIONS
This was a retrospective, nonrandomized, single center study. We studied beta-blocker type and dose at device implantation (a prespecified intention to treat type of analysis) and about 10% of the cohort switched between the two beta-blockers during the course of follow-up. Compliance with beta-blockers could not be assessed due to the retrospective study design. Programming of ICD therapies was at the discretion of the treating electrophysiologist and may have affected the incidence of the type of therapy administered for ventricular arrhythmias. However, this did not affect the combined endpoint of ICD shocks and ATP. Though the number of patients included was relatively small, this is the first real world, well matched analysis of the efficacy of these drugs in preventing ICD therapies. We limited our analysis to time to event rather than cumulative event rates since patients who receive ICD therapies are often started on other anti-arrhythmic drugs which preclude assessment of the efficacy of the beta-blocker alone. We did not collect data on heart rate which is often used as a surrogate marker for efficacy of beta blockade. However, the superiority of carvedilol over metoprolol at the highest dose equivalents suggests that factors other than rate reduction by beta1 antagonism may be at play.
Finally, residual confounders not included in the analyses may have biased our results.
| CONCLUSION
Carvedilol improves survival free of appropriate ICD therapy compared with metoprolol succinate in patients with HFrEF. Because both these drugs are now available generically, a pragmatic randomized controlled trial to study the efficacy of these drugs in HFrEF (focused on both arrhythmic and nonarrhythmic outcomes) is warranted.
